Pharmacogenetic profiling for oxaliplatin-based adjuvant chemotherapy (CT) benefit in stage II-III colon cancer (CC) patients: A GEMCAD study.
Jaime Feliú(Hospital Universitario La Paz), Paloma Cejas(Dana-Farber Cancer Institute), Rosário Madero(Hospital Universitario La Paz), Nadia Hindi(Hospital Universitario Fundación Jiménez Díaz), Javier Gállego(Hospital General Universitario de Elche), Ricardo Yayá(Fundación Instituto Valenciano de Oncología), Joan Maurel(Breast Cancer Research Foundation), Pablo Lapunzina(Hospital Universitario La Paz), Vı́ctor Moreno(Ajuntament de L’Hospitalet), Carlos Fernández-Martos(Fundación Instituto Valenciano de Oncología), Juan Antonio Moreno(Instituto Maimónides de Investigación Biomédica de Córdoba), Jorge Aparicio(Hospital Universitari i Politècnic La Fe), Jorge Barriuso(Queen's University Belfast), Ana Custodio(Hospital Universitario La Paz), Ana Calatrava(Fundación Instituto Valenciano de Oncología), Emilio Burgos(Hospital Universitario Infanta Sofía), Virginia Martínez Marín(Hospital Universitario La Paz)
Cited by 0
Related Papers
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
|JNCI Journal of the National Cancer Institute|1995|3.4k
SNPStats: a web tool for the analysis of association studies
|Bioinformatics|2006|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners
|New England Journal of Medicine|2002|806
SNPassoc: an R package to perform whole genome association studies
|Bioinformatics|2007|797